Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Retained Earnings: 2014-2024

Historic Retained Earnings for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2024 value amounting to -$469.7 million.

  • KalVista Pharmaceuticals' Retained Earnings was N/A to -$580.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$580.2 million, marking a year-over-year change of. This contributed to the annual value of -$469.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, KalVista Pharmaceuticals' Retained Earnings is -$469.7 million, which was down 286.31% from -$121.6 million recorded in FY2020.
  • In the past 5 years, KalVista Pharmaceuticals' Retained Earnings registered a high of -$121.6 million during FY2020, and its lowest value of -$469.7 million during FY2024.
  • Moreover, its 1-year median value for Retained Earnings was -$469.7 million (2024), whereas its average is -$469.7 million.
  • Data for KalVista Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 31.48% (in 2020) over the last 5 years.
  • Over the past 2 years, KalVista Pharmaceuticals' Retained Earnings (Yearly) stood at -$121.6 million in 2020, then followed by -$469.7 million in 2024.